MedTrace Logo

Clinical Trial to Assess the Efficacy and Safety of YYC405 in Type 2 Diabetes Patients

NCT05226897 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 256

Last updated 2022-06-01

No results posted yet for this study

Summary

Phase 3 study to assess the Efficacy and Safety of YYC405 in Type 2 Diabetes Patients

Conditions

Interventions

DRUG

YYC405-T

Subjects take the investigational products once a day for 24 weeks.

DRUG

Metformin≥1000mg

Subjects take the investigational products once a day for 24 weeks.

DRUG

Dapagliflozin 10mg

Subjects take the investigational products once a day for 24 weeks.

DRUG

YYC405-T placebo

Microcrystalline cellulose, Subjects take the investigational products once a day for 24 weeks.

Sponsors & Collaborators

  • Yooyoung Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Sungrae Kim, MD, Ph.D · Bucheon St Mary Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-12
Primary Completion
2022-10-31
Completion
2023-06-26

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05226897 on ClinicalTrials.gov